HSD3B1 and prostate carcinoma: While prior studies have primarily examined HSD3B1 c.1100 genotypes in prostate cancer outcomes [2,5,6] and their impact on androgen deprivation therapy response [5], emerging evidence has extended their relevance to other hormone-driven cancers such as BC and EC.